{{medical}}
{{drugbox
| Verifiedfields = changed
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = X78UG0A0RN| verifiedrevid = 407466945
| IUPAC_name = ''N''-(2-chloro-6-methylphenyl)-2-<nowiki>[[</nowiki>6-[4-(2-hydroxyethyl)-<br>1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole<br>carboxamide  monohydrate
| image = Dasatinib.svg
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}= {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2323020
| InChI1 = 1/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
| InChIKey1 = ZBNZXTGUTAYRHI-UHFFFAOYAC
| smiles = Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1421
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}= {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}= {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZBNZXTGUTAYRHI-UHFFFAOYSA-N
| CAS_number = 302962-49-8
| ATC_prefix = L01
| ATC_suffix = XE06
| PubChem = 3062316
| DrugBank = 
| C = 22 | H = 26 | N = 7 | O = 2 | S = 1 | Cl = 1
| molecular_weight = 488.01 g/mol
| bioavailability = 
| protein_bound = 96%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 1.3 to 5 hours
| excretion = Fecal (85%), [[kidney|renal]] (4%)
| licence_EU = Sprycel
| licence_US = Dasatinib
| pregnancy_AU = D
| pregnancy_US = D
| legal_US = Rx-only
| routes_of_administration = Oral
}}
'''达沙替尼'''（{{lang-en|Dasatinib}}），此前亦称'''BMS-354825'''，是一种由[[百时美施贵宝|百时美施贵宝]]生产并以“{{lang|en|Sprycel}}”为名义销售的一种癌症治疗药物。达沙替尼是一种针对[[费城染色体|费城染色体]]（{{lang|en|Philadelphia chromosome}}）和[[SRC基因|SRC基因]]（{{lang|en|Src Gene}}）变异的[[酪氨酸激酶抑制剂|酪氨酸激酶抑制剂]]，其主要用于[[伊马替尼|伊马替尼]]（{{lang|en|imatinib}}）治疗后期的[[慢性粒细胞性白血病|慢性粒细胞性白血病]]（{{lang|en|chronic myelogenous leukemia}}）以及费城染色体呈阳性的[[急性髓性白血病|急性髓性白血病]]（{{lang|en|Ph+ ALL}}）患者。该药也被证明可治疗许多其他类型的癌症，包括加速期的[[前列腺癌|前列腺癌]]<ref>{{cite journal | author = Das J ''et al.'' | title = 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-<nowiki>[[</nowiki>6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor | journal = J Med Chem | volume = 49 | issue = 23 | pages = 6819–32 | year = 2006 | pmid = 17154512 | doi = 10.1021/jm060727j}}</ref>。

== 详情 ==

===藥物作用===
在2006年6月的[[临床试验|临床试验]]中，达沙替尼是提供予对使用[[伊马替尼|伊马替尼]]而产生抗药性和依赖性的患者<ref name="pmid16775234">{{cite journal |author=Talpaz M, Shah NP, Kantarjian H, ''et al.'' |title=Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias |journal=N. Engl. J. Med. |volume=354 |issue=24 |pages=2531–41 |pmid=16775234 |doi=10.1056/NEJMoa055229 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=16775234&promo=ONFLNS19 |date=June 2006 |access-date=2011-09-16 |archive-date=2020-04-13 |archive-url=https://web.archive.org/web/20200413031420/https://www.nejm.org/doi/full/10.1056/NEJMoa055229 |dead-url=no }}</ref>，40例慢性期[[慢性粒细胞性白血病|慢性粒细胞性白血病]]患者中的37名在服用后达到了完成血液反应标准；而44例的[[加速期慢性粒细胞性白血病|加速期慢性粒细胞性白血病]]患者中有31例达到标准。


===分子靶位===
达沙替尼主要是针对[[费城染色体|费城染色体]]、[[SRC基因|SRC基因]]、[[c-Kit|c-Kit]]、[[复合弗激酶|复合弗激酶]]以及其他酪氨酸激酶，但并不针对EGFR、Her2等[[erbB激酶|erbB激酶]]。

===药效===
在慢性期的慢性粒细胞性白血病患者中有95%的病例能够平均随访时间中保持在在12个月以上药效。在加速期的患者中，82%的患者得以缓解，尽管平均随访时间只有五个月。几乎所有的急变期患者或费城染色体数值全部阳性的患者，都在6个月内恢复数值。

除了做為治療慢性粒细胞性白血病的藥物外，达沙替尼和[[槲皮素|槲皮素]]的混合物也是一種潛在的[[返老藥|返老藥]]（Senolytic），一項人體初步臨床試驗顯示，达沙替尼和槲皮素的混合物在患有糖尿病腎臟病變的人類患者中，確實會降低部分組織當中[[衰老細胞|衰老細胞]]的數量。<ref name=pmid31542391>{{cite journal |last1=Hickson |first1=LaTonya J. |last2=Langhi Prata |first2=Larissa G.P. |last3=Bobart |first3=Shane A. |last4=Evans |first4=Tamara K. |last5=Giorgadze |first5=Nino |last6=Hashmi |first6=Shahrukh K. |last7=Herrmann |first7=Sandra M. |last8=Jensen |first8=Michael D. |last9=Jia |first9=Qingyi |last10=Jordan |first10=Kyra L. |last11=Kellogg |first11=Todd A. |last12=Khosla |first12=Sundeep |last13=Koerber |first13=Daniel M. |last14=Lagnado |first14=Anthony B. |last15=Lawson |first15=Donna K. |last16=LeBrasseur |first16=Nathan K. |last17=Lerman |first17=Lilach O. |last18=McDonald |first18=Kathleen M. |last19=McKenzie |first19=Travis J. |last20=Passos |first20=João F. |last21=Pignolo |first21=Robert J. |last22=Pirtskhalava |first22=Tamar |last23=Saadiq |first23=Ishran M. |last24=Schaefer |first24=Kalli K. |last25=Textor |first25=Stephen C. |last26=Victorelli |first26=Stella G. |last27=Volkman |first27=Tammie L. |last28=Xue |first28=Ailing |last29=Wentworth |first29=Mark A. |last30=Wissler Gerdes |first30=Erin O. |last31=Zhu |first31=Yi |last32=Tchkonia |first32=Tamara |last33=Kirkland |first33=James L. |title=Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease |journal=EBioMedicine |date=September 2019 |volume=47 |pages=446–456 |doi=10.1016/j.ebiom.2019.08.069 |pmid=31542391 |pmc=6796530 }}</ref>

===受影响的基因群===
除了T315I基因突变以外，所有的费城染色体基因群都受到药物反应。

===副作用与毒性 ===
中性白细胞增多和骨髓抑制（白细胞减少）是比较普遍的毒性反应。

服用该药中的18%患者，会有并发的[[胸膜积液|胸膜积液]]/肺膜腔積水<<約35%急性患者及10%慢性患者在服食達沙替尼後出現肺膜腔積水,需要減低劑量或暫時停止治療>。一些病人会需要做[[胸腔穿刺术|胸腔穿刺术]]或[[胸膜固定术|胸膜固定术]]去治疗这种疾患。

其他严重的反应包括有中型的腹泻、外周性的[[水肿|水肿]]和[[头疼|头疼]]。

少数患者在[[肝功能试验|肝功能试验]]中显示异常。

极少[[低血钙症|低血钙症]]副作用也有出現，但是并未证明会导致任何严重问题。

也有可能引致心臟功能受損或增加流血風險。

==参考==
{{reflist|2}}

==外部链接==
*[http://www.fda.gov/cder/foi/nda/2006/021986_022072_SprycelTOC.htm Summary Basis for Approval from the U.S. Food and Drug Administration Freedom of Information homepage] {{Wayback|url=http://www.fda.gov/cder/foi/nda/2006/021986_022072_SprycelTOC.htm |date=20070311020251 }}
*[https://web.archive.org/web/20070930043921/http://www.dasatinib.com/ Prescribing information from Bristol-Myers Squibb]
*[http://www.newcmldrug.com/diary_interface/Results/Diary.asp Diary of a CML patient involved in the clinical trials for dasatinib] {{Wayback|url=http://www.newcmldrug.com/diary_interface/Results/Diary.asp |date=20110417152817 }}
*[https://web.archive.org/web/20070711095941/http://www.emea.europa.eu/humandocs/PDFs/EPAR/sprycel/H-709-PI-en.pdf Sprycel Summary of Product Characteristics] (from the European Medicines Agency website)
{{Extracellular chemotherapeutic agents}}

[[Category:鸦片类药物|Category:鸦片类药物]]
[[Category:酪氨酸激酶抑制剂|Category:酪氨酸激酶抑制剂]]
[[Category:噻唑|Category:噻唑]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:百时美施贵宝|Category:百时美施贵宝]]
[[Category:抗癌药物|Category:抗癌药物]]
[[Category:嘧啶|Category:嘧啶]]
[[Category:酰替苯胺|Category:酰替苯胺]]